nach oben

Nuclear Medicine and Molecular Imaging

Erschienen in:

29.01.2019 | Review

Progress of Coordination and Utilization of Zirconium-89 for Positron Emission Tomography (PET) Studies

verfasst von: Minh Thanh La, Van Hieu Tran, Hee-Kwon Kim

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Radiometals have been commonly used in medical applications, and utilization of such metals continues to be an attractive research area. In particular, a variety of radiometals have been developed and implemented for molecular imaging. For such applications, ⁸⁹Zr has been one of the most interesting radiometals currently used for tumor targeting. Several chemical ligands were developed as ⁸⁹Zr chelators, and new coordinating methods have also been developed more recently. In addition, immuno-positron emission tomography (PET) studies using ⁸⁹Zr-labeled monoclonal antibodies have been performed by several scientists. In this review, recent advances to the coordination of ⁸⁹Zr and the utilization of ⁸⁹Zr in PET studies are described.

Kasbollah A, Eu P, Cowell S, Deb P. Review on production of ⁸⁹Zr in a medical cyclotron for PET radiopharmaceuticals. J Nucl Med Technol. 2013;41:35–41.CrossRefPubMed

Zweit J, Downey S, Sharma HL. Production of no-carrier-added zirconium-89 for positron emission tomography. Appl Radiat Isot. 1991;42:199–201.CrossRef

Tang Y, Li S, Yang Y, Chen W, Wei H, Wang G, et al. A simple and convenient method for production of ⁸⁹Zr with high purity. Appl Radiat Isot. 2016;118:326–30.CrossRefPubMed

Link JM, Krohn KA, Eary JF, Kishore R, Lewellen TK, Johnson MW, et al. ⁸⁹Zr for antibody labeling and positron emission tomography. J Labeled Compd Radiopharm. 1986;23:1297–8.

Dejesus OT, Nickles RJ. Production and purification of ⁸⁹Zr, a potential PET antibody label. Int J Rad Appl Instrum A. 1990;41:789–90.CrossRef

Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009;36:729–39.CrossRefPubMedPubMedCentral

Walther M, Gebhardt P, Grosse-Gehling P, Würbach L, Irmler I, Preusche S, et al. Implementation of ⁸⁹Zr production and in vivo imaging of B-cells in mice with ⁸⁹Zr-labeled anti-B-cell antibodies by small animal PET/CT. Appl Radiat Isot. 2011;69:852–7.CrossRefPubMed

Siikanen J, Tran TA, Olsson TG, Strand SE, Sandell A. A solid target system with remote handling of irradiated targets for PET cyclotrons. Appl Radiat Isot. 2014;94:294–301.CrossRefPubMed

Meijs WE, Herscheid JDM, Haisma HJ, Wijbrandts R, van Langevelde F, Van Leuffen PJ, et al. Production of highly pure no-carrier added ⁸⁹Zr for the labelling of antibodies with a positron emitter. Appl Radiat Isot. 1994;45:1143–7.CrossRef

10.

Queern SL, Aweda TA, Massicano AVF, Clanton NA, El Sayed R, Sader JA, et al. Production of Zr-89 using sputtered yttrium coin targets. Nucl Med Biol. 2017;50:11–6.CrossRefPubMed

11.

Pandey MK, Engelbrecht HP, Byrne JF, Packard AB, DeGrado TR. Production of ⁸⁹Zr via the ⁸⁹Y(p,n)⁸⁹Zr reaction in aqueous solution: effect of solution composition on in-target chemistry. Nucl Med Biol. 2014;41:309–16.CrossRefPubMed

12.

Uddin MS, Khandaker MU, Kim KS, Lee YS, Lee MW, Kim GN. Excitation functions of the proton induced nuclear reactions on natural zirconium. Nucl Inst Meth Phys Res B. 2008;266:13–20.CrossRef

13.

Kandil SA, Spahn I, Scholten B, Saleh ZA, Saad SMM, Coenen HH, et al. Excitation functions of (α,xn) reactions on ^natRb and ^natSr from threshold up to 26MeV: possibility of production of ⁸⁷Y, ⁸⁸Y and ⁸⁹Zr. Appl Radiat Isot. 2007;65:561–8.CrossRefPubMed

14.

Lewis VE, Zieba KJ. A transfer standard for d + t neutron fluence and energy. Nucl Inst Meth. 1980;174:141–4.CrossRef

15.

Sadeghi M, Enferadi M, Bakhtiari M. Accelerator production of the positron emitter zirconium-89. Ann Nucl Energy. 2012;41:97–103.CrossRef

16.

Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. ⁸⁹Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010;51:1293–300.CrossRefPubMed

17.

Meijs WE, Haisma HJ, Van Der Schors R, Wijbrandts R, Van Den Oever K, Klok RP, et al. A facile method for the labeling of proteins with zirconium isotopes. Nucl Med Biol. 1996;23:439–48.CrossRefPubMed

18.

Verel I, Visser GWM, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GAMS. ⁸⁹Zr immuno-PET: comprehensive procedures for the production of ⁸⁹Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271–81.PubMed

19.

Lewis MR, Shively JE. Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions. Bioconjug Chem. 1998;9:72–86.CrossRefPubMed

20.

Perk LR, Vosjan MJWD, Visser GWM, Budde M, Jurek P, Kiefer GE, et al. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging. 2010;37:250–9.CrossRefPubMed

21.

Vosjan MJWD, Perk LR, Visser GWM, Budde M, Jurek P, Kiefer GE, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5:739.CrossRefPubMed

22.

Gao F, Ieritano C, Chen KT, Dias GM, Rousseau J, Bénard F, et al. Two bifunctional desferrioxamine chelators for bioorthogonal labeling of biovectors with zirconium-89. Org Biomol Chem. 2018;16:5102–6.CrossRefPubMed

23.

White DL, Durbin PW, Jeung N, Raymond KN. Specific sequestering agents for the actinides. 16. Synthesis and initial biological testing of polydentate oxohydroxypyridinecarboxylate ligands. J Med Chem. 1988;31:11–8.CrossRefPubMed

24.

Allott L, Da Pieve C, Meyers J, Spinks T, Ciobota DM, Kramer-Marek G, et al. Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89. Chem Commun. 2017;53:8529–32.CrossRef

25.

Patra M, Bauman A, Mari C, Fischer CA, Blacque O, Häussinger D, et al. An octadentate bifunctional chelating agent for the development of stable zirconium-89 based molecular imaging probes. Chem Commun. 2014;50:11523–5.CrossRef

26.

Vugts DJ, Klaver C, Sewing C, Poot AJ, Adamzek K, Huegli S, et al. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for ⁸⁹Zr-immuno-PET. Eur J Nucl Med Mol Imaging. 2017;44:286–95.CrossRefPubMed

27.

Guérard F, Lee Y-S, Tripier R, Szajek LP, Deschamps JR, Brechbiel MW. Investigation of Zr(iv) and ⁸⁹Zr(iv) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging. Chem Commun. 2013;49:1002–4.CrossRef

28.

Rousseau J, Zhang Z, Wang X, Zhang C, Lau J, Rousseau E, et al. Synthesis and evaluation of bifunctional tetrahydroxamate chelators for labeling antibodies with ⁸⁹Zr for imaging with positron emission tomography. Bioorganic Med Chem Lett. 2018;28:899–905.CrossRef

29.

Zhai C, Summer D, Rangger C, Franssen GM, Laverman P, Haas H, et al. Novel bifunctional cyclic chelator for ⁸⁹Zr labeling–radiolabeling and targeting properties of RGD conjugates. Mol Pharm. 2015;12:2142–50.CrossRefPubMedPubMedCentral

30.

Adams CJ, Wilson JJ, Boros E. Multifunctional desferrichrome analogues as versatile ⁸⁹Zr(IV) chelators for immunoPET probe development. Mol Pharm. 2017;14:2831–42.CrossRefPubMedPubMedCentral

31.

Liu S, Edwards DS. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug Chem. 2001;12:7–34.CrossRefPubMed

32.

Seibold U, Wängler B, Wängler C. Rational design, development, and stability assessment of a macrocyclic four-hydroxamate-bearing bifunctional chelating agent for ⁸⁹Zr. Chem Med Chem. 2017;12:1555–71.CrossRefPubMed

33.

Deri MA, Ponnala S, Zeglis BM, Pohl G, Dannenberg JJ, Lewis JS, et al. Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO). J Med Chem. 2014;57:4849–60.CrossRefPubMedPubMedCentral

34.

Bhatt NB, Pandya DN, Xu J, Tatum D, Magda D, Wadas TJ. Evaluation of macrocyclic hydroxyisophthalamide ligands as chelators for zirconium-89. PLoS One. 2017;12:e0178767–e77.CrossRefPubMedPubMedCentral

35.

Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110:2858–902.CrossRefPubMedPubMedCentral

36.

Pandya DN, Bhatt N, Yuan H, Day CS, Ehrmann BM, Wright M, et al. Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. Chem Sci. 2017;8:2309–14.CrossRefPubMed

37.

Börjesson PKE, Jauw YWS, Boellaard R, de Bree R, Comans EFI, Roos JC, et al. Performance of immuno–positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006;12:2133–40.CrossRefPubMed

38.

Rizvi SN, Visser OJ, Vosjan MJ, van Lingen A, Hoekstra OS, Zijlstra JM, et al. Biodistribution, radiation dosimetry and scouting of ⁹⁰Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using ⁸⁹Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging. 2012;39:512–20.CrossRefPubMedPubMedCentral

39.

Gaykema SBM, Brouwers AH, Lub-de Hooge MN, Pleijhuis RG, Timmer-Bosscha H, Pot L, et al. ⁸⁹Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med. 2013;54:1014–8.CrossRefPubMed

40.

van Asselt SJ, Oosting SF, Brouwers AH, Bongaerts AHH, de Jong JR, Lub-de Hooge MN, et al. Everolimus reduces ⁸⁹Zr-bevacizumab tumor uptake in patients with neuroendocrine tumors. J Nucl Med. 2014;55:1087–92.CrossRefPubMed

41.

den Hollander MW, Bensch F, Glaudemans AW, Oude Munnink TH, Enting RH, den Dunnen WF, et al. TGF-β antibody uptake in recurrent high-grade glioma imaged with ⁸⁹Zr-fresolimumab PET. J Nucl Med. 2015;56:1310–4.CrossRef

42.

Lamberts LE, Menke-van der Houven van Oordt CW, ter Weele EJ, Bensch F, Smeenk MM, Voortman J, et al. ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody–drug conjugate treatment. Clin Cancer Res. 2016;22:1642–52.CrossRefPubMed

43.

van Loon J, Even AJG, Aerts HJWL, Öllers M, Hoebers F, van Elmpt W, et al. PET imaging of zirconium-89 labelled cetuximab: a phase I trial in patients with head and neck and lung cancer. Radiother Oncol. 2017;122:267–73.CrossRefPubMed

44.

Jauw YWS, Zijlstra JM, de Jong D, Vugts DJ, Zweegman S, Hoekstra OS, et al. Performance of ⁸⁹Zr-labeled-rituximab-PET as an imaging biomarker to assess CD20 targeting: a pilot study in patients with relapsed/refractory diffuse large B cell lymphoma. PLoS One. 2017;12:e0169828.CrossRefPubMedPubMedCentral

45.

Bensch F, Lamberts LE, Smeenk MM, Jorritsma-Smit A, Lub-de Hooge MN, Terwisscha van Scheltinga AGT, et al. ⁸⁹Zr lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment in patients with solid tumors. Clin Cancer Res. 2017;23:6128–37.CrossRefPubMedPubMedCentral

46.

van Es SC, Brouwers AH, Mahesh SVK, Leliveld-Kors AM, de Jong IJ, Lub-de Hooge MN, et al. ⁸⁹Zr-bevacizumab PET: potential early read out for efficacy of everolimus in metastatic renal cell carcinoma patients. J Nucl Med. 2017;58:905–10.CrossRefPubMed

47.

Bensch F, Brouwers AH, Lub-de Hooge MN, de Jong JR, van der Vegt B, Sleijfer S, et al. ⁸⁹Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. Eur J Nucl Med Mol Imaging. 2018;45:2300–6.CrossRefPubMedPubMedCentral

48.

Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. ⁸⁹Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852–8.CrossRefPubMed

49.

Ulaner GA, Hyman DM, Ross DS, Corben A, Chandarlapaty S, Goldfarb S, et al. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using ⁸⁹Zr-trastuzumab PET/CT. J Nucl Med. 2016;57:1523–8.CrossRefPubMedPubMedCentral

50.

Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database of Syst Rev. 2012.

51.

Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, et al. Optimal regimen of trastuzumab in combination with oxaliplatin/capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. BMC Cancer. 2016;16:68.CrossRefPubMedPubMedCentral

52.

Gaykema SBM, Schröder CP, Vitfell-Rasmussen J, Chua S, Oude Munnink TH, Brouwers AH, et al. ⁸⁹Zr-trastuzumab and ⁸⁹Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. Clin Cancer Res. 2014;20:3945–54.CrossRefPubMed

53.

Bahce I, Huisman MC, Verwer EE, Ooijevaar R, Boutkourt F, Vugts DJ, et al. Pilot study of ⁸⁹Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer. EJNMMI Res. 2014;4:35.CrossRefPubMedPubMedCentral

54.

Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, et al. ⁸⁹Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. J Nucl Med. 2015;56:63–9.CrossRefPubMed

55.

Oordt CWM-vH, Gootjes EC, Huisman MC, Vugts DJ, Roth C, Luik AM, et al. ⁸⁹Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget. 2015;6:30384–93.

56.

Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, et al. ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:2093–105.CrossRefPubMedPubMedCentral

57.

ter Weele EJ, Terwisscha van Scheltinga AGT, Kosterink JGW, Pot L, Vedelaar SR, Lamberts LE, et al. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts. Oncotarget. 2015;6:42081–90.PubMedPubMedCentral

Titel: Progress of Coordination and Utilization of Zirconium-89 for Positron Emission Tomography (PET) Studies
verfasst von: Minh Thanh La
Van Hieu Tran
Hee-Kwon Kim
Publikationsdatum: 29.01.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Nuclear Medicine and Molecular Imaging / Ausgabe 2/2019
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-019-00584-z

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Tracer Accumulation in Relation to Venous Thrombus on 18F-DOPA PET/CT in a Case of Persistent Hyperinsulinemic Hypoglycemia of Infancy

Gallbladder Paraganglioma Associated with SDHD Mutation: a Potential Pitfall on 18F-FDOPA PET Imaging

Development of Predictive Models in Patients with Epiphora Using Lacrimal Scintigraphy and Machine Learning

Theranostics in Bangladesh: Current Status, Challenges, and Future Perspective

Assessment of Left Ventricular Ejection Fraction by Thallium-201 Myocardial SPECT-CT in Patients with Angina Pectoris: Comparison with 2D Echocardiography

Nuclear Theranostics in Taiwan